References
- Elens L , HesselinkDA, van Schaik RH et al. Pharmacogenetics in kidney transplantation: recent updates and potential clinical applications. Mol. Diagn. Ther.16(6) , 331–345 (2012).
- Zuo X , NgCM, BarrettJS et al. Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis. Pharmacogenet. Genomics 23(5) , 251–261 (2013).
References
- Chakkera HA , ChangYH, BodnerJK et al. Genetic differences in Native Americans and tacrolimus dosing after kidney transplantation. Transplant. Proc. 45(1) , 137–141 (2013).
References
- Elens L , HesselinkDA, van Schaik RH et al. Pharmacogenetics in kidney transplantation: recent updates and potential clinical applications. Mol. Diagn. Ther.16(6) , 331–345 (2012).
- Shi Y , LiY, TangJ et al. Influence of CYP3A4, CYP3A5 and MDR-1 polymorphisms on tacrolimus pharmacokinetics and early renal dysfunction in liver transplant recipients. Gene 512(2) , 226–231 (2013).
- Elens L , van Gelder T, Hesselink DA et al.CYPA4*44: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy. Pharmacogenomics14(1) , 47–62 (2013).
References
- Elens L , HesselinkDA, van Schaik RH et al. Pharmacogenetics in kidney transplantation: recent updates and potential clinical applications. Mol. Diagn. Ther.16(6) , 331–345 (2012).
- Bosó V , HerreroMJ, BeaS et al. Increased hospital stay and allograft dysfunction in renal transplant recipients with Cyp2c19 AA variant in SNP rs4244285. Drug Metab. Dispos. 41(2) , 480–487 (2013).